BACKGROUND/AIMS: Anxiety and depression are common inpatients with cognitive decline and Alzheimer's disease (AD), and recognition and treatment of these symptoms can improve their quality of life. The present study investigates anxiety and depression in different phases of cognitive decline. METHODS: The sample consisted of five groups of elderly people in different phases of cognitive decline; four from a community-based sample (Longitudinal Aging Study Amsterdam), and one group of elderly people diagnosed with AD. ANOVAs were performed to investigate group differences in the severity and prevalence of anxiety and depression, and comorbid anxiety and depressive symptoms. RESULTS: The prevalence rates of anxiety, comorbid anxiety and depressive symptoms and depressive symptoms follow a pattern of an increasing prevalence as cognitive performance declines and a decrease in the prevalence when cognitive functioning is severely impaired. AD patients report fewest anxiety symptoms. CONCLUSION: We found that the prevalence of anxiety symptoms, depressive symptoms and comorbid anxiety and depressive symptoms seems to increase in the early phase of cognitive decline, and decreases as cognitive functioning further declines. Elderly diagnosed with AD report less anxiety as expected, probably due to lack of insight caused by AD. 2007 S. Karger AG, Basel
BACKGROUND/AIMS: Anxiety and depression are common inpatients with cognitive decline and Alzheimer's disease (AD), and recognition and treatment of these symptoms can improve their quality of life. The present study investigates anxiety and depression in different phases of cognitive decline. METHODS: The sample consisted of five groups of elderly people in different phases of cognitive decline; four from a community-based sample (Longitudinal Aging Study Amsterdam), and one group of elderly people diagnosed with AD. ANOVAs were performed to investigate group differences in the severity and prevalence of anxiety and depression, and comorbid anxiety and depressive symptoms. RESULTS: The prevalence rates of anxiety, comorbid anxiety and depressive symptoms and depressive symptoms follow a pattern of an increasing prevalence as cognitive performance declines and a decrease in the prevalence when cognitive functioning is severely impaired. ADpatients report fewest anxiety symptoms. CONCLUSION: We found that the prevalence of anxiety symptoms, depressive symptoms and comorbid anxiety and depressive symptoms seems to increase in the early phase of cognitive decline, and decreases as cognitive functioning further declines. Elderly diagnosed with AD report less anxiety as expected, probably due to lack of insight caused by AD. 2007 S. Karger AG, Basel
Authors: Suzanne C Danhauer; Claudine Legault; Hanna Bandos; Kelley Kidwell; Joseph Costantino; Leslie Vaughan; Nancy E Avis; Steve Rapp; Laura H Coker; Michelle Naughton; Cecile Naylor; Antonio Terracciano; Sally Shumaker Journal: Neuropsychol Dev Cogn B Aging Neuropsychol Cogn Date: 2012-12-14
Authors: Alvaro Camacho; Wassim Tarraf; Daniel E Jimenez; Linda C Gallo; Patricia Gonzalez; Robert C Kaplan; Melissa Lamar; Tasneem Khambaty; Bharat Thyagarajan; Krista M Perreira; Rosalba Hernandez; Jianwen Cai; Martha L Daviglus; Sylvia Wassertheil-Smoller; Hector M González Journal: Am J Geriatr Psychiatry Date: 2017-07-03 Impact factor: 4.105
Authors: Robert H Pietrzak; Paul Maruff; Michael Woodward; Julia Fredrickson; Amy Fredrickson; John H Krystal; Steven M Southwick; David Darby Journal: Am J Geriatr Psychiatry Date: 2012-03 Impact factor: 4.105
Authors: Tatiana Perrino; Craig A Mason; Scott C Brown; Arnold Spokane; José Szapocznik Journal: J Gerontol B Psychol Sci Soc Sci Date: 2008-09 Impact factor: 4.077
Authors: M Elovainio; M Kivimäki; J E Ferrie; D Gimeno; R De Vogli; M Virtanen; J Vahtera; E J Brunner; M G Marmot; A Singh-Manoux Journal: J Epidemiol Community Health Date: 2009-06 Impact factor: 3.710
Authors: Julie A Graziane; Joanne C Beer; Beth E Snitz; Chung-Chou H Chang; Mary Ganguli Journal: Am J Geriatr Psychiatry Date: 2015-10-22 Impact factor: 4.105